Novel quinazoline-based α-antagonists, (DZ-50) have been developed by our group, impair primary growth and progression of renal and prostate cancer to metastasis by inhibiting focal adhesion kinase (FAK) phosphorylation and protein kinase B (AKT) signaling pathways by inducing anoikis. This evidence concerns the gene AKT1 and prostate carcinoma.